Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published Date April 2008 Volume 2008:4(2) Pages 337—344

DOI http://dx.doi.org/10.2147/TCRM.S1209

Published 21 April 2008

Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Applications of gold nanoparticles in cancer nanotechnology

Weibo Cai, Ting Gao, Hao Hong, Jiangtao Sun

Nanotechnology, Science and Applications 2008, 1:17-32

Published Date: 19 September 2008

A study on the preparation and characterization of plasmid DNA and drug-containing magnetic nanoliposomes for the treatment of tumors

Wang Z-Y, Wang L, Zhang J, Li Y-T, Zhang D-S

International Journal of Nanomedicine 2011, 6:871-875

Published Date: 27 April 2011

Synthesis and properties of a novel biodegradable poly(ester amine) copolymer based on poly(L-lactide) and low molecular weight polyethylenimine for gene delivery

Guo QF, Liu TT, Yan X, Wang XH, Shi S, Luo F, Qian ZY

International Journal of Nanomedicine 2011, 6:1641-1649

Published Date: 11 August 2011

Biocompatibility of Fe3O4@Au composite magnetic nanoparticles in vitro and in vivo

Li Y, Liu J, Zhong Y, Zhang J, Wang Z, Wang L, An Y, Lin M, Gao Z, Zhang D

International Journal of Nanomedicine 2011, 6:2805-2819

Published Date: 9 November 2011

Synthesis and characterization of electrospun polyvinyl alcohol nanofibrous scaffolds modified by blending with chitosan for neural tissue engineering

Naghavi Alhosseini S, Moztarzadeh F, Mozafari M, Asgari S, Dodel M, Samadikuchaksaraei A, Kargozar S, Jalali N

International Journal of Nanomedicine 2012, 7:25-34

Published Date: 4 January 2012

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gold M, Lorenzl S, Stewart AJ, Morimoto BH, Williams DR, Gozes I

Neuropsychiatric Disease and Treatment 2012, 8:85-93

Published Date: 9 February 2012